Preferences help
enabled [disable] Abstract
Number of results
2018 | 65 | 2 | 303-308
Article title

Deficiency of long-chain polyunsaturated fatty acids in phenylketonuria: a cross-sectional study

Title variants
Languages of publication
The etiology of altered blood fatty acid (FA) profile in phenylketonuria (PKU) is understood only partially. We aimed to determine whether FAs deficiency is dependent on the diet or metabolic disturbances. The study comprised 40 PKU patients (20 female, 20 male; aged 11 to 35 years; 12 children and 28 adults) and 40 healthy subjects (HS; 20 female, 20 male, aged 18 to 33 years). We assessed the profile of FAs (gas chromatography/mass spectrometry) and analyzed the 72-hour dietary recalls. The amount of C14:0, C16:0 and C16:1n-7, C18:1n-9 did not differ between the analyzed groups. The percentage of C18:0 was higher, while C20:3n-9, C18:2n-6, C20:2n-6, C20:4n-6, C22:4n-6, C22:5n-6 and C22:6n-3 was lower in PKU than in HS. However, C18:3n-6, C18:3n-3 and n-6/n-3 ratio were higher in PKU patients. The C20:4n-6/C20:3n-6 ratio (reaction catalyzed by Δ5-desaturase), the C22:5n-6/C22:4n-6 and the C22:6n-3/C22:5n-3 ratio (both reactions catalyzed by Δ6 desaturase) were significantly lower in PKU patients. Therefore, the deficiency of long-chain polyunsaturated fatty acids in PKU patients may result not only from inadequate supply but also from metabolic disturbances.
Physical description
  • Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland
  • Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland
  • Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland
  • Department of Organization and Management in Health Care, Poznan University of Medical Sciences, Poznań, Poland
  • Voivodeship Hospital, Wrocław, Poland
  • Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland
  • Acosta PB, Yannicelli S, Singh R, Eisas LJ, Kennedy MJ, Bernstein L, Rohr F, Trahms C, Koch R, Breck J (2001) Intake and blood levels of fatty acids in treated patients with phenylketonuria. J Pediatr Gastroenterol Nutr 33: 253-259.
  • Agostoni C, Braegger C, Decsi T, Kolacek S, Mihatsch W, Moreno LA, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J (2011) Supplementation of N-3 LCPUFA to the diet of children older than 2 years: a commentary by the ESPGHAN Committee on nutrition. J Pediatr Gastroenterol Nutr 53: 2-10.doi: 10.1097/MPG.0b013e318216f009.
  • Agostoni C, Verduci E, Massetto N, Fiori L, Radaelli G, Riva E, Giovannini M (2003) Long term effects of long chain polyunsaturated fats in hyperphenylalaninemic children. Arch Dis Child 88: 582-583.
  • Al Hafid N, Christodoulou J (2015) Phenylketonuria: a review of current and future treatments. Transl Pediatr 4: 304-317.doi: 10.3978/j.issn.2224-4336.2015.10.07.
  • Beblo S, Reinhardt H, Demmelmair H, Muntau AC, Koletzko B (2007) Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J Pediatr 150: 479-484.doi: 10.1016/j.jpeds.2006.12.011.
  • Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F, European PKU centers (2010) Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab 99: 109-115.doi: 10.1016/j.ymgme.2009.09.005.
  • Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U, (2011) Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 104 (Suppl: S2-S9).doi: 10.1016/j.ymgme.2011.08.017.
  • Bosdet T, Branov J, Selvage C, Yousefi M, Sirrs S (2015) Diet history is a reliable predictor of suboptimal docosahexaenoic acid levels in adult patients with phenylketonuria. JIMD Reports 21: 97-102.
  • Calder PC (2012) Mechanisms of action of (n-3) fatty acids. J Nutr 142: 592S-599S.doi: 10.3945/jn.111.155259.
  • Drzymała-Czyż S, Krzyżanowska P, Koletzko B, Nowak J, Miśkiewicz-Chotnicka A, Moczko J, Lisowska A, Walkowiak J (2017) Determinants of serum glycerophospholipid fatty acids in cystic fibrosis. Int J Mol Sci 18: E185.doi: 10.3390/ijms18010185.
  • Feillet F, Agostoni C (2010) Nutritional issues in treating phenylketonuria. J Inherit Metab Dis 33: 659-664.doi: 10.1007/s10545-010-9043-4.
  • Giovannini M, Verduci E, Radaelli G, Lammardo A, Minghetti D, Cagnoli G, Salvatici E, Riva E (2011) Long-chain polyunsaturated fatty acids profile in plasma phospholipids of hyperphenylalaninemic children on unrestricted diet. Prostaglandins Leukot Essent Fatty Acids 84: 39-42.doi: 10.1016/j.plefa.2010.09.003.
  • Giovannini M, Verduci E, Salvatici E, Paci S, Riva E (2012) Phenylketonuria: nutritional advances and challenges. Nutr Metab (Lond) 9: 7.doi: 10.1186/1743-7075-9-7.
  • Glaser C, Demmelmair H, Koletzko B (2010) High-throughput analysis of fatty acid composition of plasma glycerophospholipids. J Lipid Res 51: 216-221.doi: 10.1194/jlr.D000547.
  • Gramer G, Haege G, Langhans CD, Schuhmann V, Burgard P, Hoffmann GF (2016) Long-chain polyunsaturated fatty acid status in children, adolescents and adults with phenylketonuria. Prostaglandins Leukot Essent Fatty Acids 109: 52-57.doi: 10.1016/j.plefa.2016.04.005.
  • Htun P, Nee J, Ploeckinger U, Eder K, Geisler T, Gawaz M, Bocksch W, Fateh-Moghadam S (2015) Fish-free diet in patients with phenylketonuria is not associated with early atherosclerotic changes and enhanced platelet activation. PloS One 10: e0135930.doi: 10.1371/journal.pone.0135930.
  • Infante JP, Huszagh VA (2001) Impaired arachidonic (20:4n-6) and docosahexaenoic (22:6n-3) acid synthesis by phenylalanine metabolites as etiological factors in the neuropathology of phenylketonuria. Mol Genet Metab 72: 185-198.doi: 10.1006/mgme.2001.3148.
  • Jarosz M (2012) Nutrition standards for the Polish population. Instytut Żywności i Żywienia (in Polish)
  • Koletzko B, Beblo S, Demmelmair H, Müller-Felber W, Hanebutt FL (2009) Does dietary DHA improve neural function in children? Observations in phenylketonuria. Prostaglandins Leukot Essent Fatty Acids 81: 159-164.doi: 10.1016/j.plefa.2009.06.006.
  • Koletzko B, Sauerwald T, Demmelmair H, Herzog M, von Schenck U, Böhles H, Wendel U, Seidel J (2007) Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial. J Inherit Metab Dis 30: 326-332.doi: 10.1007/s10545-007-0491-4.
  • Lage S, Bueno M, Andrade F, Prieto JA, Delgado C, Legarda M, Sanjurjo P, Aldámiz-Echevarría LJ (2010) Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density. J Inherit Metab Dis 33: S363-371.doi: 10.1007/s10545-010-9189-0.
  • Lohner S, Fekete K, Decsi T (2013) Lower n-3 long-chain polyunsaturated fatty acid values in patients with phenylketonuria: a systematic review and meta-analysis. Nutr Res 33: 513-520.doi: 10.1016/j.nutres.2013.05.003.
  • Moore SA, Hurt E, Yoder E, Sprecher H, Spector AA (1995) Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J Lipid Res 36: 2433-2443.
  • Moseley K, Koch R, Moser AB (2002) Lipid status and long-chain polyunsaturated fatty acid concentrations in adults and adolescents with phenylketonuria on phenylalanine-restricted diet. J Inherit Metab Dis 25: 56-64.
  • Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, Rae C, Green K, Wilcken B, Christodoulou J (2007) The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab 91: 48-54.doi: 10.1016/j.ymgme.2007.02.002.
  • Schuck PF, Malgarin F, Cararo JH, Cardoso F, Streck EL, Ferreira GC (2015) Phenylketonuria pathophysiology: on the role of metabolic alterations. Aging Dis 6: 390-399.doi: 10.14336/AD.2015.0827.
  • Scriver C, Beaudet A, Sly W, Valle D (2001) The Metabolic and Molecular Bases of Inherited Disease, 8th edn. ed. McGraw Hill.
  • Shefer S, Tint GS, Jean-Guillaume D, Daikhin E, Kendler A, Nguyen LB, Yudkoff M, Dyer CA (2000) Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse? J Neurosci Res 61: 549-563.
  • Singh RH, Cunningham AC, Mofidi S, Douglas TD, Frazier DM, Hook DG, Jeffers L, McCune H, Moseley KD, Ogata B, Pendyal S, Skrabal J, Splett PL, Stembridge A, Wessel A, Rohr F (2016) Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach. Mol Genet Metab 118: 72-83.doi: 10.1016/j.ymgme.2016.04.008.
  • van Gool CJ, van Houwelingen AC, Hornstra (2000) The essential fatty acid status in phenylketonuria patients under treatment. J Nutr Biochem 11: 543-547.
  • van Wegberg AM, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, van Rijn M, Trefz F, Walter JH, van Spronsen FJ (2017) The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 12: 162.doi: 10.1186/s13023-017-0685-2.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.